Reckitt Benckiser Group Plc agreed to sell most of its homecare business to private equity firm Advent International for an enterprise value of up to $4.8 billion as the UK consumer goods company focuses on faster-growing operations.
Reckitt said it will retain a 30% stake in the business, whose brands include Air Wick air fresheners and Cillit Bang cleaners. The enterprise value includes up to about $1.3 billion of contingent and deferred consideration, the company said Friday.
Shares of Reckitt rose as much as 2.3% in early London trading before paring back some of the gains. The stock is up nearly 14% in the past 12 months through Thursday’s close.
Chief Executive Officer Kris Licht last year announced plans to sell some of Reckitt’s non-core homecare brands and review options for its infant formula business. The proposed sale was part of his strategy to streamline Reckitt and focus on faster growing parts of the business, after a difficult few years where consumer goods companies have had to contend with stretched consumer budgets and shoppers trading down to unbranded products.
Reckitt’s homecare unit was boosted during the pandemic when demand for cleaners and disinfectants soared, but those benefits have diminished. The company now expects faster growth from consumer-health labels like Strepsils lozenges, Durex condoms and Mucinex cold remedies, while retaining better performing home-care brands like Lysol and Dettol.
Reckitt expects to pay a special dividend of $2.2 billion to shareholders following the completion of the deal, which is expected by Dec 31. It will also incur one-time costs of about $800 million related to the transaction.
Barclays Plc and Citigroup Inc. advised Advent, while Goldman Sachs Group Inc. and Morgan Stanley were lead financial advisers to Reckitt.
The valuation for the businesses being sold is below the initial £6 billion ($8 billion) Reckitt sought when it put the brands up for sale last year, Bloomberg News reported earlier. Potential buyers, which also included Lone Star Funds, pitched valuations in a lower range of £3 billion to £4 billion, according to people familiar with the matter.
The deal represents a compromised exit of the asset, according to David Hayes and Molly Wylenzek, equity analysts at Jefferies. “At only a net value of £3 billion it is up to £1 billion lower than many had hoped,” they said in a note.
Reckitt’s sale process was hit with anxiety around US tariffs, which has cast uncertainty over the the outlook for global businesses with international manufacturing. The deal has been structured so that the greater risk in the current market environment is shared between the two parties, with Reckitt retaining a stake and needing to hit certain milestones to generate the full payout.
With a lot resting on a successful execution of a deal for the homecare assets this outcome should still “be a boost to management’s credibility,” according to James Edwardes Jones and Wassachon Udomsilpa, RBC analysts. They said it will enable investors to focus more closely on the core Reckitt business in a note to clients.
The deal will be financed with about €2 billion ($2.3 billion) of term loans, denominated in euros and dollars, underwritten by a group of banks and it’s expected to be syndicated to institutional investors post summer.
In March Reckitt said it expects modest sales growth this year as it reshapes the business — a move it said would deliver a significantly stronger performance starting in 2026.
The infant formula unit, created by the $17 billion acquisition of Mead Johnson in 2017, remains a sore point for Reckitt. Licht acknowledged last year that the unit, which has been hit by legal woes in the US, hasn’t always been a natural fit in the group.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
